Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish

Haematologica

Volumn 97, Issue 12, 2012, Pages 1895-1903

  Onnebo, Sara M N ^a   Rasighaemi, Parisa ^a   Kumar, Janani ^a   Liongue, Clifford ^a   Ward, Alister C ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Leukemia; Oncogenesis; TEL JAK2; Zebrafish

Indexed keywords

GELATINASE B; JANUS KINASE 2; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR ETV6;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EMBRYO; FUSION GENE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; LYMPHOPOIESIS; MYELOPOIESIS; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZEBRA FISH;

ANIMALS; CELL LINEAGE; CELLS, CULTURED; EMBRYO, NONMAMMALIAN; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; ONCOGENE PROTEINS, FUSION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-TYROSINE KINASES; TRANSCRIPTION FACTORS; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84870410309     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.064659     Document Type: Article

References (70)

1. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007;282(28):20059-63.
2. O'Sullivan LA, Liongue C, Lewis RS, Stephenson SEM, Ward AC. Cytokine receptor signaling through the Jak/Stat/Socs pathway in disease. Mol Immunol. 2007;44 (10):2497-506.
3. Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 2008;14(12):3716-21.
4. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205 (4):751-8.
5. Xiang Z, Zhao Y, Mitaksov V, Fremont DH, Kasai Y, Molitoris A, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood. 2008;111 (9):4809-12.
6. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006;10(1):65-75.
7. Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia. 2007;21(3):574-6.
8. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-61.
9. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.
10. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8.
11. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106(4):1207-9.
12. Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HS, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene. 2006;25(9):1434-6.
13. Gouilleux-Gruart B, Gouilleux F, Desaint C, Claisse JF, Capiod JC, Delobel J, et al. STAT- related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 1996;87 (5):1692-7.
14. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997;159(10):4720-8.
15. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood. 2000;95(1):19-29.
16. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90(7):2535-40.
17. Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene. 2005;24(48):7248-52.
18. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, et al. A TEL- JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278(5341):1309-12.
19. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myeloand lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17(18):5321-33.
20. Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel M-T, et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood. 2000;95(12):3891-9.
21. Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, Mayeux P, et al. Transforming properties of chimeric TEL- JAK proteins in Ba/F3 cells. Blood. 2000;95(6):2076-83.
22. Luo H, Rose P, Barber D, Hanratty WP, Lee S, Roberts TM, et al. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol. 1997;17(3):1562-71.
23. Feener EP, Rosario F, Dunn SL, Stancheva Z, Myers MGJ. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signalling. Mol Cell Biol. 2004;24(11):4968-78.
24. Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol. 2011;18(9):971-6.
25. Ho JM-Y, Beattie BK, Squire JA, Frank DA, Barber DL. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood. 1999;93(12):4354-64.
26. dos Santos NR, Ghysdael J. A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia. Leukemia. 2006;20 (1):182-5.
27. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, et al. Stat5 is essential for the myeloand lymphoproliferative disease induced by TEL/JAK2. Mol Cell. 2000;6(3):693-704.
28. Monni R, Santos SC, Mauchauffe M, Berger R, Ghysdael J, Gouilleux F, et al. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells. Oncogene. 2001;20(7):849-58.
29. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. Socs-1 inhibits TEL-JAK2- mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteosomal-mediated degradation. Mol Cell Biol. 2001;21(10):3547-57.
30. Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M, et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem. 2001;276(16):12530-8.
31. Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JMY, Nguyen MHH, et al. The tumor suppressor activity of SOCS-1. Oncogene. 2002;21(28):4351-62.
32. Kalev-Zylinska ML, Horsfield JA, Flores MV, Postlethwait JH, Vitas MR, Baas AM, et al. Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis. Development. 2002;129(8):2015-30.
33. Langenau DM, Traver D, Ferrando AA, Kutok JL, Aster JC, Kanki JP, et al. Mycinduced T cell leukemia in transgenic zebrafish. Science. 2003;299(5608):887-90.
34. Onnebo SMN, Condron MM, McPhee DO, Lieschke GJ, Ward AC. Hematopoietic perturbation in zebrafish expressing a tel-jak2a fusion. Exp Hematol. 2005;33(2):182-8.
35. Ma AC, Fan A, Ward AC, Liongue C, Lewis RS, Cheng SH, et al. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera. Exp Hematol. 2009;37(12):1379-86.
36. Oates AC, Brownlie A, Pratt SJ, Irvine DV, Liao EC, Paw BH, et al. Gene duplication of zebrafish JAK2 homologs is accompanied by divergent embryonic expression patterns: only jak2a is expressed during erythropoiesis. Blood. 1999;94(8):2622-36.
37. Turner DL, Weintraub H. Expression of achaete-scute homolog 3 in Xenopus embryos converts ectoderm cells to a neural fate. Genes Dev. 1994;8(12):1434-47.
38. Ma AC, Ward AC, Liang R, Leung AY. The role of jak2a in zebrafish hematopoiesis. Blood. 2007;110(6):1824-30.
39. O'Sullivan LA, Noor SM, Trengove MC, Lewis RS, Liongue C, Sprigg NS, et al. Suppressor of cytokine signaling 1 regulates embryonic myelopoiesis independently of its effects on T cell development. J Immunol. 2011;186(8):4751-61.
40. Ward AC, McPhee DO, Condron MM, Varma S, Cody SH, Onnebo SMN, et al. The zebrafish spi1 promoter drives myeloid-specific expression in stable transgenic fish. Blood. 2003;102(9):3238-40.
41. Bennett CM, Kanki JP, Rhodes J, Liu TX, Paw BH, Kieran MW, et al. Myelopoiesis in the zebrafish, Danio rerio. Blood. 2001;98(3):643-51.
42. Lieschke GJ, Oates AC, Paw BH, Thompson MA, Hall NE, Ward AC, et al. Zebrafish SPI- 1(PU.1) marks a site of myeloid development independent of primitive erythropoiesis: implications for axial patterning. Dev Biol. 2002;246(2):274-95.
43. Detrich HW 3rd, Kieran MW, Chan FY, Barone LM, Yee K, Rundstadler JA, et al. Intraembryonic hematopoietic cell migration during vertebrate development. Proc Natl Acad Sci USA. 1995;92(23):10713-7.
44. Crosier PS, Bardsley A, Horsfield JA, Krassowska AK, Lavallie ER, Collins-Racie LA, et al. In situ hybridisation screen in zebrafish for the selection of gene encoding secreted proteins. Dev Dyn. 2001;222(4): 637-44.
45. Yoong S, O'Connell B, Soanes A, Crowhurst MO, Lieschke GJ, Ward AC. Characterization of the zebrafish matrix metalloproteinase 9 gene and its developmental expression pattern. Gene Expr Patterns. 2007;7(1-2):39-46.
46. Long Q, Meng A, Wang H, Jessen JR, Farrell MJ, Lin S. GATA-1 expression pattern can be recapitulated in living transgenic zebrafish using GFP reporter gene. Development. 1997;124(20):4105-11.
47. Meng A, Tang H, Ong BA, Farrell MJ, Lin S. Promoter analysis in living zebrafish embryos identifies a cis-acting motif required for neuronal expression of GATA-2. Proc Natl Acad Sci USA. 1997;94(12):6267-72.
48. Trede NS, Zapata A, Zon LI. Fishing for lymphoid genes. Trends Immunol. 2001;22(6): 302-7.
49. Willett CE, Cortes A, Zuasti A, Zapata A. Early hematopoiesis and developing lymphoid organs in the zebrafish. Dev Dyn. 1999;214(4):323-36.
50. Lewis RS, Stephenson SEM, Ward AC. Constitutive activation of zebrafish stat5 expands hematopoietic cell populations in vivo. Exp Hematol. 2006;34(2):179-87.
51. Trede NS, Langenau DM, Traver D, Look AT, Zon LI. The use of zebrafish to understand immunity. Immunity. 2004;20(4):367-79.
52. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol. 2004;22:55-79.
53. Campbell PJ, Griesshammer M, Dohner H, Kusec R, Hasselbalch HC, Larsen TS, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107(5):2098-100.
54. Staerk J, Kallin A, Royer Y, Diaconu CC, Dusa A, Demoulin JB, et al. JAK2, the JAK2 V617F mutant and cytokine receptors. Pathol Biol (Paris). 2007;55(2):88-91.
55. Morgan KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med. 2008;59:213-22.
56. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W, et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood. 2007;109(11):4924-9.
57. Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest. 2004;114(11): 1650-8.
58. Malinge S, Monni R, Bernard O, Penard-Lacronique V. Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha. Oncogene. 2006;25(25): 3589-97.
59. Nguyen MH, Ho JM, Beattie BK, Barber DL. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway. J Biol Chem. 2001;276(35):32704-13.
60. Ho JM, Nguyen MH, Dierov JK, Badger KM, Beattie BK, Tartaro P, et al. TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood. 2002;100(4):1438-48.
61. Funakoshi-Tago M, Tago K, Nishizawa C, Takahashi K, Mashino T, Iwata S, et al. Licochalcone A is a potent inhibitor of TEL- Jak2-mediated transformation through the specific inhibition of Stat3 activation. Biochem Pharmacol. 2008;76(12):1681-93.
62. Dawson MA, Curry JE, Barber K, Beer PA, Graham B, Lyons JF, et al. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disroders. Br J Haematol. 2010;150(1):46-57.
63. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem. 2002;277(49):47954-63.
64. De Keersmaecker K, Cools J. Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia. 2006;20(2):200-5.
65. Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia. 2008;22 (1):87-95.
66. Barahmand-Pour F, Meinke A, Groner B, Decker T. Jak2-Stat5 interactions analyzed in yeast. J Biol Chem. 1998;273(20):12567-75.
67. May P, Gerhartz C, Heesel B, Welte T, Doppler W, Graeve L, et al. Comparative study on the phosphotyrosine motifs of different cytokine receptors involved in STAT5 activation. FEBS Lett. 1996;394(2):221-6.
68. Pezet A, Ferrag F, Kelly PA, Edery M. Tyrosine docking sites of the rat prolactin receptor required for association and activation of Stat5. J Biol Chem. 1997;272(40): 25043-50.
69. Ward AC, Hermans MHA, Smith L, van Aesch YM, Schelen AM, Antonissen C, et al. Tyrosine-dependent and independent mechanisms of STAT3 activation by the human granulocyte colony-stimulating factor (GCSF) receptor are differentially utilized depending on G-CSF concentration. Blood. 1999;93(1):113-24.
70. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2009;106(23):9414-8.